The Greek scientist behind the new drug for Alzheimer
Approved by the FDA new drug to treat the disease
The aducanumab of Biogen Inc as the first treatment for an underlying cause ofdisease Alzheimer’sapproved Monday o FDA Drug Agency of USA.
It is the first drug in almost 20 years to receive approval. The production company Biogen estimates that about 1.5 million Americans are eligible for antucanumab treatment.
According to Reuters, Biogen together with the Japanese company Eisai Co stopped the drug development test in March 2019 and then resumed the tests in October, saying that a more detailed data analysis showed that some patients with very early forms of the disease benefited from taking higher doses for a long time.
However, as with Pfizer’s Albert Burla and the coronavirus vaccine, another Greek is hiding behind this important development for global health.
Dr. Stelios Papadopoulos is the Chairman of the Board of Biogen. He has been a member of the Board of Directors of the company since 2008 and was appointed chairman in June 2014.
Dr. Stelios Papadopoulos is the Chairman of the Board of Directors of Biogen. He has been a member of the company’s Board of Directors since 2008 and was appointed chairman in June 2014.
Papadopoulos is a former investment banker specializing in life sciences companies. He was a member of the teaching staff of the Department of Cell Biology at the Medical School of New York University, and is now an Associate Professor of Cell Biology at the same University.
He is a member of the Audit Committee, the Finance Committee and the Science and Technology Committee. Dr. Papadopoulos is the Chairman of the Board of Exelixis Inc., a drug discovery and development company he co-founded in 1994. He founded Anadys Pharmaceuticals Inc. in 2000, and was a member of its Board of Directors until its acquisition by Hoffman-La Roche in 2011, where he was Chairman of the Board in 2011.
In the non-profit sector, Dr. Papadopoulos is co-founder and chairman of Fondation Santé, Member of the Board of Visitors of Duke Medicine and Member of the Duke Advisory Board Global Advisory Committee on Health Innovation.
Dr. Papadopoulos retiredas Vice President of Cowen & Co., LLC, a financial services company in 2006, after six years with the company, where as an investment banker, he focused on biotechnology and the pharmaceutical sector.
Prior to joining Cowen, he spent 13 years as an investment banker at PaineWebber, Inc., most recently as president of PaineWebber Development Corp, a biotechnology subsidiary of PaineWebber. He joined PaineWebber in 1987 from Drexel Burnham Lambert, where as an analyst in the Equity Research Department, he covered the biotechnology industry. Prior to Drexel, he was Donaldson biotechnology analyst Lufkin & Jenrette.
He is Pontian on his father’s side and Asia Minor on his mother’s side. He was born in 1948 and grew up in Thessaloniki, in Charilaou, and is a follower of Mars.
In fact, in June 2020, taking part in a teleconference on “The current health crisis and biomedical research in Greece”, talking to other Greek scientists who also excel abroad, made the difference. At the end of the teleconference and having an Mars flag behind him throughout the conversation, at his home in New York, he said: “To my friends in Thessaloniki and Greece I have to say, Mars Religion, Gate 3”.
Although he went to the Technical University of Athens, Stelios Papadopoulos studied for only three months and left for the USA, where he began his studies in West Virginia. There he completed his studies in Mathematics, Physics and Biology, did a postgraduate course in Pittsburgh and then turned to Biophysics.
With further studies in Economics, he soon switched from academia to investment, as a biotechnology stock analyst on Wall Street. Since then, its course is constantly on the rise.
In an interview with “Kathimerini” about a year ago, he said: “Science is like football. You can not play ball alone and win a game. You need teammates and opponents. If some teams are made, it will start. “system to work and pay off. Investors will come too. Money has no homeland: it chases investment opportunities.”